PropThink’s Weekly Biotech Roundup
Recap - A dual event in the obesity space this week, the U.S. FDA approved Orexigen Therapeutics’ (OREX) weight loss pill Contrave just one day before an … Continue Reading
Read nowSearch Results for orexigen
Trading Biotech Stocks Around FDA Approval Decisions Is Rarely Cut and Dry
It Seems the Ebola Trade is Still On After All
Recap - BOOM! Shares of Tekmira Pharmaceuticals (TKMR) climbed from $14 to $20 into Friday’s close after the FDA removed a clinical hold on the company’s Ebola therapeutic, essentially enabling its … Continue Reading
Read nowThis Week’s Small-Cap Healthcare Roundup
Insights - Tekmira Pharmaceuticals (TKMR) was the momentum stock of the week as the spread of Ebola continues in Guinea, Liberia and Sierra Leone, and two infected Americans … Continue Reading
Read now
Don’t Misunderstand EnteroMedics’ Positive Panel Vote
Insights - The U.S. FDA’s Advisory Gastroenterology and Urology Devices Panel (GUDP) voted on Tuesday 6 to 2 (one abstention) that the relative benefits of EnteroMedics’ (ETRM) VBLOC vagal blocking … Continue Reading
Read nowOur Top Stories In Biotech This Week
Recap - Orexigen Therapeutics (OREX) got an unexpected surprise on Wednesday when the FDA extended its review of the New Drug Application for NB32, the company’s investigational drug … Continue Reading
Read nowThe Market Makes All-Time Highs While Biotech Continues the Malaise
Insights - Before we get into the event of the week – the ASCO abstract drop on Wednesday evening – lets take a look at what’s been … Continue Reading
Read now